Presidio Medical vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Presidio Medical develops an ultra-low frequency (ULF) spinal cord stimulation platform for nociceptive lower back pain; raised $102M total including $72M Series C from Deerfield; 95% responder rate in trials.
About
Presidio Medical is a clinical-stage medical technology company developing a next-generation neuromodulation platform for treating chronic nociceptive lower back pain. Founded in 2017 and headquartered in South San Francisco, California, the company''s Ultra Low Frequency (ULF™) Neuromodulation System delivers precisely calibrated, ultra-low frequency electrical pulses through spinal cord stimulation (SCS) electrodes to inhibit neuronal pain responses localized to the lower back — without relying on paresthesia (the tingling sensation associated with older SCS devices).
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.